Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

Nuclear factor-kappaB (NF-kappaB) has an important role in multiple myeloma (MM) cell pathogenesis in the context of the bone marrow (BM) microenvironment. In NF-kappaB signaling cascades, IkappaB kinase alpha (IKKalpha) and IKKbeta are key molecules that predominantly mediate noncanonical and canonical pathways, respectively. In this study, we examined the biologic sequelae of the inhibition of IKKalpha versus IKKbeta in MM cell lines. All MM cell lines have constitutive canonical NF-kappaB activity, and a subset of MM cell lines shows noncanonical NF-kappaB activity. Adhesion to BM stromal cells further activates both canonical and noncanonical NF-kappaB activity. IKKbeta inhibitor MLN120B blocks canonical pathway and growth of MM cell lines but does not inhibit the noncanonical NF-kappaB pathway. Although IKKalpha knockdown induces significant growth inhibition in the cell lines with both canonical and noncanonical pathways, it does not inhibit NF-kappaB activation. Importantly, IKKalpha down-regulation decreases expression of beta-catenin and aurora-A, which are known to mediate MM cell growth and survival. Finally, IKKbeta inhibitor enhances the growth inhibition triggered by IKKalpha down-regulation in MM cells with both canonical and noncanonical NF-kappaB activity. Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM.

[1]  K. Anderson,et al.  Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells , 2007, British journal of haematology.

[2]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[3]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[4]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[5]  D. Carrasco,et al.  Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma , 2007, Proceedings of the National Academy of Sciences.

[6]  A. Protopopov,et al.  The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis , 2007, Cancer cell.

[7]  J. Ruland,et al.  Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.

[8]  C. Waes.  Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer , 2007 .

[9]  S. Sen,et al.  Targeting aurora kinases as therapy in multiple myeloma. , 2006, Blood.

[10]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.

[11]  J. Ruland,et al.  Aberrant NF- κ B Signaling in Lymphoma: Mechanisms, Consequences and Therapeutic Implications , 2006 .

[12]  R. Gaynor,et al.  IKKα Regulates the Mitotic Phase of the Cell Cycle by Modulating Aurora A Phosphorylation , 2006, Cell cycle.

[13]  Hiroshi Yasui,et al.  MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo , 2006, Clinical Cancer Research.

[14]  N. Munshi,et al.  Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.

[15]  M. Hepperle,et al.  A Selective Small Molecule IκB Kinase β Inhibitor Blocks Nuclear Factor κB-Mediated Inflammatory Responses in Human Fibroblast-Like Synoviocytes, Chondrocytes, and Mast Cells , 2006, Journal of Pharmacology and Experimental Therapeutics.

[16]  H. J. Kim,et al.  NF-κB and IKK as therapeutic targets in cancer , 2006, Cell Death and Differentiation.

[17]  Hiroshi Yasui,et al.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. , 2005, Blood.

[18]  T. Libermann,et al.  Antimyeloma activity of heat shock protein-90 inhibition. , 2005, Blood.

[19]  N. Munshi,et al.  MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[21]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[22]  J. Shaughnessy,et al.  Wnts induce migration and invasion of myeloma plasma cells. , 2005, Blood.

[23]  Keisuke Ito,et al.  1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo. , 2005, Cancer research.

[24]  P. Richardson,et al.  TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. , 2004 .

[25]  P. Richardson,et al.  Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment , 2004, Clinical Cancer Research.

[26]  C. Scheidereit,et al.  Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation , 2004, Oncogene.

[27]  R. Nusse,et al.  Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Gaynor,et al.  IκB kinases: key regulators of the NF-κB pathway , 2004 .

[29]  C. Scheidereit,et al.  Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. , 2004, Oncogene.

[30]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[31]  K. Anderson,et al.  Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. , 2003, Cancer research.

[32]  K. Anderson,et al.  NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. , 2003, Blood.

[33]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[34]  W. Dalton,et al.  Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells , 2003, Oncogene.

[35]  J. Rubin,et al.  Wnt signaling in B-cell neoplasia , 2003, Oncogene.

[36]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[37]  R. Gaynor,et al.  IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. , 2003, Molecular biology of the cell.

[38]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[40]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[41]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[42]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[43]  R. Gaynor,et al.  Regulation of β-Catenin Function by the IκB Kinases* , 2001, The Journal of Biological Chemistry.

[44]  A. Baldwin,et al.  Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity* , 2001, The Journal of Biological Chemistry.

[45]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[46]  Chris Albanese,et al.  NF-κB and cell-cycle regulation: the cyclin connection , 2001 .

[47]  R. Gaynor,et al.  Regulation of beta-catenin function by the IkappaB kinases. , 2001, The Journal of biological chemistry.

[48]  W. Dalton,et al.  Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.

[49]  R. Gaynor,et al.  IkB Kinase a (IKKa) Regulation of IKKb Kinase Activity , 2000 .

[50]  Claus Scheidereit,et al.  NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition , 1999, Molecular and Cellular Biology.

[51]  C. Ferran,et al.  Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-κB , 1999 .

[52]  E. Zandi,et al.  The IκB Kinase Complex (IKK) Contains Two Kinase Subunits, IKKα and IKKβ, Necessary for IκB Phosphorylation and NF-κB Activation , 1997, Cell.

[53]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[54]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .